Publications

Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, Abraham C, Banerjee S, Leung RA, Tewari AK et al..  2012.  Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.. Diagn Mol Pathol. 21(2):61-8.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Rodrigues DNava, Robinson D, Omlin A, Tunariu N et al..  2015.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.. N Engl J Med. 373(18):1697-708.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Rodrigues DNava, Robinson D, Omlin A, Tunariu N et al..  2015.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.. N Engl J Med. 373(18):1697-708.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.

Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..  2016.  A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C et al..  2016.  Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.. Sci Rep. 6:24146.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.

Beltran H, Danila D, B M, Szmulewitz R., Vaishampayan U, Armstrong A., Stein M., Hoimes C, Pinski J., Scher H. et al..  2016.  A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.